Drug intelligence / Profile preview

Colabone

Development stage: Unknown
Lead developer: Vivapharm
Modality: Small Molecules, Peptides
Administration: Oral

Overview

Colabone is an OTC consumer health supplement developed by Gelita and distributed by Vivapharm. It is formulated to support bone health, promote bone remodeling, and accelerate fracture repair in individuals with osteopenia or osteoporosis. The supplement contains Fortibone (a patented blend of bioactive collagen peptides developed by Gelita), calcium lactate, and vitamin D3. Fortibone works by stimulating osteoblasts to increase extracellular bone matrix production and inhibiting osteoclast-mediated bone resorption, while calcium lactate and vitamin D3 support bone mineralization and calcium absorption.

Brand names: Colabone

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Colabone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Colabone.

Explore the full profile